Healthcare / Diagnostics & ResearchNasdaqGM
$8.71
-0.61 (-6.55%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 28% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-13.4M · quality 59.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
90/100
SEC 100%
Sin guardar todavía.
Market Cap
$92M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-10.3%
↓Gross Margin
74.7%
↑Debt/Equity
0.08
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2018–2025 · 7 años de histórico normalizado
Revenue CAGR
-13.3%
FCF CAGR
—
FCF margin
-6.2%
FCF / Net income
0.61x
Latest source
SEC-backed
Margin decomposition
Último año: revenue $77.2M · net income $-7.9M · FCF $-4.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025SEC | 2024SEC | 2023SEC | 2022SEC | 2021SEC | 2020SEC | 2019SEC | 2018SEC |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | $77.2M | $77.2M | $70.7M | $75.7M | $81.7M | $79.7M | $65.9M | $381.7M | $208.9M |
| Net Income | $-7.9M | $-7.9M | $-47.5M | $-92.1M | $-140.8M | $-125.0M | $-62.4M | $-169.2M | $-177.5M |
| EBITDA | $-32.0M | $-32.0M | $-288.5M | $-517.9M | $-856.3M | — | — | — | — |
| EPS | -5.20 | -5.20 | -33.70 | -63.80 | -93.50 | — | — | — | — |
| Gross Margin | 74.7% | 74.7% | 70.3% | 67.6% | 67.5% | 71.7% | 73.0% | 71.6% | 64.7% |
| Operating Margin | -10.2% | -10.2% | -69.3% | -124.5% | -174.1% | -156.9% | -95.9% | -44.3% | -77.3% |
| Net Margin | -10.3% | -10.3% | -67.2% | -121.6% | -172.4% | -156.9% | -94.7% | -44.3% | -85.0% |
| Balance Sheet | |||||||||
| Debt/Equity | 0.08 | 0.08 | 0.09 | 0.02 | 0.04 | 0.00 | 0.01 | — | — |
| Current Ratio | 2.99 | 2.99 | — | — | — | — | — | — | — |
| Cash Flow | |||||||||
| Free Cash Flow | $-4.8M | $-4.8M | $-13.4M | $-37.2M | $-75.2M | $-107.1M | $-20.5M | $-271.0M | $-172.0M |
| Returns | |||||||||
| ROE | -10.3% | -10.3% | -59.7% | -85.1% | -83.8% | -43.2% | -16.8% | -19.0% | -29.4% |
| Valuation | |||||||||
| P/B | 0.17 | 0.17 | 0.12 | 0.12 | 0.24 | — | — | — | — |
| Growth & Yield | |||||||||
| Revenue Growth | 9.2% | 9.2% | -6.6% | -7.3% | 2.5% | 21.0% | -82.7% | 82.7% | — |
| EPS Growth | 84.6% | 84.6% | 47.2% | 31.8% | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+181.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-33.70 → -5.20
Residual
+181.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.